Postgraduate Education, Jiangxi University of Traditional Chinese Medicine.
Respiratory Department, Jingdezhen Hospital of Traditional Chinese Medicine.
Medicine (Baltimore). 2021 Apr 30;100(17):e25713. doi: 10.1097/MD.0000000000025713.
There is no optimal treatment to alleviate the decline of lung function in the stable phase of chronic obstructive pulmonary disease (COPD). The effectiveness of moxibustion as an adjunctive treatment for COPD in the stable phase has been reported clinically, but the conclusions on efficacy and safety have not been unified. This study will systematically evaluate the efficacy and safety of moxibustion on the treatment of COPD in the stable phase, providing clinical-based evidence.
We will systematically search 7 literature databases and 2 clinical trial registration platforms. The searching time will be conducted from the establishment of databases to March 31, 2021, regardless of language. We will include the randomized controlled trial (RCT) evaluation of moxibustion combined with basic therapy vs basic therapy alone for the treatment of stable COPD. We will assess the risk of bias for individual RCTs using the Cochrane Handbook 5.1.0 evaluation tool. The primary outcome is forced expiratory volume in 1 second/forced vital capacity. The secondary outcomes include forced expiratory volume in 1 second, forced vital capacity, six-minute walking distance, COPD assessment test score, maximum ventilation, response to treatment, and incidence of adverse events. We will collect the effective data of individual RCT through systematic analysis of the random effect model. Heterogeneity will be tested by Cochran Q test and I-squared statistics. Two subgroup analyses will be performed to explore the sources of heterogeneity based on clinical experience. Excluding RCTs with a high risk of bias, fixed-effect model will be used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias will be assessed by funnel plot and Egger test.
This study will provide systematic evidence on the efficacy and safety of moxibustion on the treatment of patients with stable COPD through strict quality assessment and reasonable data synthesis. We hope that the results will be submitted to a peer-reviewed journal for publication.
This systematic review will provide the best current evidence for the adjuvant treatment of stable COPD with moxibustion.
INPLASY202140047.
目前尚无缓解慢性阻塞性肺疾病（COPD）稳定期肺功能下降的最佳治疗方法。艾灸作为 COPD 稳定期的辅助治疗方法在临床上已有报道，但疗效和安全性的结论尚未统一。本研究将系统评价艾灸治疗 COPD 稳定期的疗效和安全性，为临床提供循证依据。
我们将系统检索 7 个文献数据库和 2 个临床试验注册平台。检索时间从数据库建立到 2021 年 3 月 31 日，不考虑语言。我们将纳入艾灸联合基础治疗与基础治疗单独治疗 COPD 稳定期的随机对照试验（RCT）评价。我们将使用 Cochrane 手册 5.1.0 评价工具评估单个 RCT 的偏倚风险。主要结局为 1 秒用力呼气量/用力肺活量。次要结局包括 1 秒用力呼气量、用力肺活量、6 分钟步行距离、COPD 评估测试评分、最大通气量、治疗反应和不良反应发生率。我们将通过系统分析随机效应模型来收集单个 RCT 的有效数据。采用 Cochran Q 检验和 I-squared 统计量检验异质性。根据临床经验进行 2 项亚组分析，以探索异质性的来源。排除偏倚风险高的 RCT 后，采用固定效应模型进行敏感性分析，以检验荟萃分析结果的稳健性。采用漏斗图和 Egger 检验评估发表偏倚。
通过严格的质量评估和合理的数据综合，本研究将为艾灸治疗稳定期 COPD 患者的疗效和安全性提供系统证据。我们希望研究结果能提交给同行评议的期刊发表。
本系统评价将为艾灸治疗稳定期 COPD 提供当前最佳证据。
INPLASY 注册号：INPLASY202140047。
